Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study
In incurable ALK+ NSCLC, alectinib appears effective as first-line therapy regardless of brain metastases. EML4-ALK fusions occur in smokers, and smoking may reduce TTD. These findings, limited by the small cohort, require confirmation in larger studies but may still help guide treatment predictions and strategies.
Authors
- Emma Roger Andersen
- Peter Meldgaard (ORCID: https://orcid.org/0000-0002-5788-4463)
- Bo Sorensen
- Miroslaw Stelmach
- Karin Holmskov Hansen (ORCID: https://orcid.org/0009-0000-7619-8779)
- Tine McCulloch
- Maiken Parm Ulhøi
- Lars Munch Larsen
- Christoffer Trier Maansson
- Jon Lykkegaard Andersen
Institutions
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Zealand University Hospital (DK)
- Næstved Sygehus (DK)
- Ringsted Sygehus (DK)
- Aalborg University (DK)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100993
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00